• United Therapeutics won a Delaware federal court ruling that Liquidia’s Yutrepia infringed two claims of its U.S. Patent No. 11,826,327.
• Decision covered Yutrepia’s PH-ILD use; court rejected Liquidia’s bid to invalidate the claims.
• Company plans to seek an order directing the FDA to withdraw Yutrepia’s NDA approval, potentially removing it until labeling drops PH-ILD.
• United Therapeutics also intends to pursue monetary damages for past infringement, including a possible royalty on Yutrepia sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260930122219) on September 30, 2026, and is solely responsible for the information contained therein.